Oramed Pharmaceuticals

Yahoo Finance • 2 years ago

Oramed to Present at the 83rd American Diabetes Association Conference

NEW YORK, June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83r... Full story

Yahoo Finance • 2 years ago

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune... Full story

Yahoo Finance • 2 years ago

The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But it would be foolish to simply accept every extremely large loss as an inevitable part of the game. We wouldn't blame Ora... Full story

Yahoo Finance • 2 years ago

Oramed’s oral insulin pill fails; stock is down 72%

MARKET PULSE Shares of Oramed Pharmaceuticals Inc. (ORMP) plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clini... Full story

Yahoo Finance • 2 years ago

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3... Full story

Yahoo Finance • 3 years ago

Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week

Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) stock has had a really bad year. To wit the share price is down 58% in that time. On the other hand... Full story